Nerandomilast

1 paper

6 trials, 4 about aging

6 of 6 trials sponsored by its developers

Trials

4 about aging, of 5

About aging

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
Phase 3Active, not recruiting
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
Phase 3Recruiting
A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases
Phase 3Active, not recruiting
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
Phase 3Not yet recruiting

Development

Companies: Boehringer IngelheimPhase 3idiopathic pulmonary fibrosis, progressive pulmonary fibrosis

Trial sponsors

Boehringer Ingelheim
Company5 trialsPhase 32,851 people

Latest

1 in 12 months

Frontiers in MedicineMay 7

Beyond attenuation: a translational review of curative-intent pharmacological targets in idiopathic pulmonary fibrosis

ReviewIdiopathic pulmonary fibrosis